Medications

Combined therapy makes headway for liver cancer

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...

Oncology & Cancer

Exploring ferroptosis and its implications in lung cancer

An estimated 2.2 million people suffer from lung cancer worldwide, making it the second most common type of cancer. Though improvements in treatment have been made, the overall survival rate of lung cancer patients is low, ...

page 1 from 40